Devraj Sukul1, Milan Seth1, Theodore Schreiber2, George Hanzel3, Akshay Khandelwal4, Louis A Cannon5, Thomas A Lalonde6, Hitinder S Gurm1,7. 1. Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan. 2. Detroit Medical Center-Cardiovascular Institute, Detroit, Michigan. 3. Division of Cardiology, Department of Medicine, William Beaumont Hospital, Heart and Vascular, Royal Oak, Michigan. 4. Division of Cardiology, Henry Ford Health System, Detroit, Michigan. 5. McLaren-Northern Michigan Regional Hospital, Petoskey, Michigan. 6. Department of Cardiovascular Medicine, St. John Hospital and Medical Center, Detroit, Michigan. 7. Cardiovascular Medicine, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.
Abstract
OBJECTIVES: We sought to evaluate the patterns of use and outcomes associated with eptifibatide and abciximab administration among dialysis patients who underwent percutaneous coronary intervention (PCI). BACKGROUND: Contraindicated medications are frequently administered to dialysis patients undergoing PCI often resulting in adverse outcomes. Eptifibatide is a glycoprotein IIb/IIIa inhibitor that is often used during PCI and is contraindicated in dialysis. METHODS: We included dialysis patients who underwent PCI from January 2010 to September 2015 at 47 hospitals in Michigan. We compared outcomes between patients who received eptifibatide compared with abciximab. Both groups required concurrent treatment with unfractionated heparin only. In-hospital outcomes included repeat PCI, bleeding, major bleeding, need for transfusion, and death. Optimal full matching was used to adjust for non-random drug administration. RESULTS: Of 177 963 patients who underwent PCI, 4303 (2.4%) were on dialysis. Among those, 384 (8.9%) received eptifibatide and 100 (2.3%) received abciximab. Prior to matching, patients who received eptifibatide had higher pre-procedural hemoglobin levels (11.3 g/dL vs. 10.7 g/dL; P < 0.001) and less frequently had a history of myocardial infarction (36.5% vs. 52.0%; P = 0.005). After matching, there were no significant differences in in-hospital outcomes between eptifibatide and abciximab including transfusion (aOR: 1.15; 95%CI: 0.55-2.40; P = 0.70), bleeding (1.47; 0.64-3.40; P = 0.36), major bleeding (4.68; 0.42-52.3; P = 0.21), repeat PCI (0.38; 0.03-4.23; P = 0.43), and death (1.53; 0.2-9.05; P = 0.64). CONCLUSIONS: Despite being contraindicated in dialysis, eptifibatide was used approximately 3.5 times more frequently than abciximab among dialysis patients undergoing PCI but was associated with similar in-hospital outcomes.
OBJECTIVES: We sought to evaluate the patterns of use and outcomes associated with eptifibatide and abciximab administration among dialysis patients who underwent percutaneous coronary intervention (PCI). BACKGROUND: Contraindicated medications are frequently administered to dialysis patients undergoing PCI often resulting in adverse outcomes. Eptifibatide is a glycoprotein IIb/IIIa inhibitor that is often used during PCI and is contraindicated in dialysis. METHODS: We included dialysis patients who underwent PCI from January 2010 to September 2015 at 47 hospitals in Michigan. We compared outcomes between patients who received eptifibatide compared with abciximab. Both groups required concurrent treatment with unfractionated heparin only. In-hospital outcomes included repeat PCI, bleeding, major bleeding, need for transfusion, and death. Optimal full matching was used to adjust for non-random drug administration. RESULTS: Of 177 963 patients who underwent PCI, 4303 (2.4%) were on dialysis. Among those, 384 (8.9%) received eptifibatide and 100 (2.3%) received abciximab. Prior to matching, patients who received eptifibatide had higher pre-procedural hemoglobin levels (11.3 g/dL vs. 10.7 g/dL; P < 0.001) and less frequently had a history of myocardial infarction (36.5% vs. 52.0%; P = 0.005). After matching, there were no significant differences in in-hospital outcomes between eptifibatide and abciximab including transfusion (aOR: 1.15; 95%CI: 0.55-2.40; P = 0.70), bleeding (1.47; 0.64-3.40; P = 0.36), major bleeding (4.68; 0.42-52.3; P = 0.21), repeat PCI (0.38; 0.03-4.23; P = 0.43), and death (1.53; 0.2-9.05; P = 0.64). CONCLUSIONS: Despite being contraindicated in dialysis, eptifibatide was used approximately 3.5 times more frequently than abciximab among dialysis patients undergoing PCI but was associated with similar in-hospital outcomes.
Authors: Eva Kline-Rogers; David Share; Diane Bondie; Bruce Rogers; Dean Karavite; Sherri Kanten; Patricia Wren; Cindy Bodurka; Cathy Fisk; John McGinnity; Susan Wright; Susan Fox; Kim A Eagle; Mauro Moscucci Journal: J Interv Cardiol Date: 2002-10 Impact factor: 2.279
Authors: Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting Journal: J Am Coll Cardiol Date: 2011-11-07 Impact factor: 24.094
Authors: Hitinder S Gurm; Dean E Smith; J Stewart Collins; David Share; Arthur Riba; Andrew J Carter; Thomas LaLonde; Eva Kline-Rogers; Michael O'Donnell; Hameem Changezi; Marcel Zughaib; Robert Safian; Mauro Moscucci Journal: J Am Coll Cardiol Date: 2008-02-05 Impact factor: 24.094
Authors: David A Share; Darrell A Campbell; Nancy Birkmeyer; Richard L Prager; Hitinder S Gurm; Mauro Moscucci; Marianne Udow-Phillips; John D Birkmeyer Journal: Health Aff (Millwood) Date: 2011-04 Impact factor: 6.301
Authors: Derek P Chew; A Michael Lincoff; Hitinder Gurm; Katherine Wolski; David J Cohen; Tim Henry; Frederick Feit; Eric J Topol Journal: Am J Cardiol Date: 2005-03-01 Impact factor: 2.778
Authors: Thomas T Tsai; Thomas M Maddox; Matthew T Roe; David Dai; Karen P Alexander; P Michael Ho; John C Messenger; Brahmajee K Nallamothu; Eric D Peterson; John S Rumsfeld Journal: JAMA Date: 2009-12-09 Impact factor: 56.272
Authors: Giuseppe De Luca; Harry Suryapranata; Gregg W Stone; David Antoniucci; James E Tcheng; Franz-Josef Neumann; Frans Van de Werf; Elliott M Antman; Eric J Topol Journal: JAMA Date: 2005-04-13 Impact factor: 56.272
Authors: Chiara Melloni; Stefan K James; Jennifer A White; Robert P Giugliano; Robert A Harrington; Kurt Huber; Pierluigi Tricoci; Paul W Armstrong; Frans Van de Werf; Gilles Montalescot; Robert M Califf; L Kristin Newby Journal: Am Heart J Date: 2011-11 Impact factor: 4.749
Authors: Roxana Mehran; Eugenia Nikolsky; Alexandra J Lansky; Ajay J Kirtane; Young-Hak Kim; Frederick Feit; Steven Manoukian; Jeffrey W Moses; Ramin Ebrahimi; E Magnus Ohman; Harvey D White; Stuart J Pocock; George D Dangas; Gregg W Stone Journal: JACC Cardiovasc Interv Date: 2009-08 Impact factor: 11.195